Alzheimer’s Disease Therapeutics 2021 Market Forecast and Analysis

In-detail Table of Contents of Alzheimer’s Disease Therapeutics in Major Developed Markets to 2021 Market Research

Scope for this research:

·         The AD market has a lack of therapeutic options.

·         Which classes of drug dominate the market?

·         What newly approved therapies have entered the market?

·         How do the leading marketed therapies compare clinically?

·         How will the new therapies be positioned in the treatment of AD?

·         How have selected late-stage pipeline therapies performed in clinical trials?

The pipeline contains a range of molecule types and molecular targets, including those that are well established in AD, and novel, first-in-class therapies.

·         Which molecular targets appear most frequently in the pipeline?

·         AD clinical trials have an overall attrition rate of 94%.

·         What are the failure rates for individual Phases of clinical development?

·         How do AD clinical trial characteristics, including failure rate, duration, and size compare against respiratory and industry averages?

The AD market is forecast to rise from a value of $5.2 billion in 2014 to $11.3 billion in 2021, at a CAGR of 11.8% across the eight major markets assessed.

·         How much of a role will disease prevalence and new product approvals play in market growth?

·         Will generic competition have a significant impact on the market over the forecast period?

There have been 170 licensing deals and 104 co-development deals pertaining to AD products since 2006.

·         Which territories show the most deal activity?

·         What were the trends in deal completion by product stage of development?

·         What were the conditions of the key licensing or co-development deals to take place in AD?

Get sample for this research .

Reasons to buy this research:

·         Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in AD.

·         Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies, and a heatmap directly comparing safety and efficacy data.

·         Analyze the AD pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.

·         Predict growth in market size in eight major markets, with in-depth market forecasting from 2014 to 2021. The forecasts will provide an understanding of how epidemiology trends, new drug entries, and patent expirations will influence market value.

·         Identify commercial opportunities in the AD deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

Complete research report at .